基因介导的LDL胆固醇差异与静脉血栓栓塞风险
本研究利用UK Biobank和All of Us两个大型生物库的全基因组测序数据,评估基因介导的LDL-C差异与VTE风险的关联。结果显示,LDLR、APOB和PCSK9罕见功能变异虽导致LDL-C显著差异(高达约50%),但并未一致增加VTE风险,提示LDL-C本身对静脉血栓形成可能无大效应。
要点
- LDL-C的基因介导差异未一致关联VTE风险。
- 罕见变异负荷的Meta分析OR范围为0.60至1.07。
- 既往LDL-C与VTE的关联可能部分反映代谢和肥胖通路。
核心结论
- 在两个大型生物库中,基因介导的LDL-C差异与VTE风险无一致关联,提示LDL-C本身不太可能对静脉血栓风险产生大效应,但小效应不能排除。
研究设计与样本
- 研究分析了UK Biobank(430,049人)和All of Us(283,609人)的全基因组测序数据,评估LDLR、APOB、PCSK9罕见功能变异及常见PCSK9 R46L变异与LDL-C和VTE的关联。
主要发现
- LDLR、APOB和PCSK9罕见功能变异导致基因特异性LDL-C差异高达约50%。
- 罕见变异负荷与VTE的关联在各队列间不一致,Meta分析OR范围为0.60至1.07。
- 敏感性和前瞻性分析结果相似,阳性对照分析显示已知易栓症变异与VTE的预期关联。
临床怎么用
- 对于VTE风险评估,基因介导的LDL-C差异可能不是主要关注因素。
- 降脂治疗对VTE的 modest 获益可能不完全由LDL-C介导,需考虑代谢和肥胖等通路。
局限性
- 研究可能无法排除LDL-C对VTE的小效应。
- 既往观察性关联可能受代谢和肥胖等混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a common and clinically significant cardiovascular condition. Although low-density lipoprotein (LDL) cholesterol is causally linked to atherosclerotic disease, its role in VTE remains unclear. Meta-analyses of randomized trials have suggested modest reductions in VTE with lipid-lowering therapy, but whether these effects are LDL mediated is uncertain. OBJECTIVES: This study sought to evaluate whether lifelong genetically mediated differences in low-density lipoprotein cholesterol (LDL-C) are associated with VTE risk. METHODS: Whole-genome sequencing data from 430,049 UK Biobank and 283,609 All of Us participants were analyzed. Rare protein-truncating and AlphaMissense-predicted damaging missense variants (minor allele frequency <0.1%) in LDLR, APOB, and PCSK9, as well as the common PCSK9 R46L variant, were evaluated. Associations with LDL-C were assessed using linear regression, and VTE associations using Firth logistic regression with fixed-effect meta-analysis. Incident VTE was evaluated using Cox models. RESULTS: Rare functional variants in LDLR, APOB, and PCSK9 produced substantial gene-specific differences in LDL-C (up to ∼50% differences). Despite these marked lifelong differences, rare variant burdens were not consistently associated with VTE across cohorts, although smaller effect sizes could not be excluded. Meta-analyzed ORs ranged from 0.60 to 1.07. Sensitivity and prospective analyses yielded similar findings. Complementary common variant and multivariable Mendelian randomization analyses suggested that previously reported LDL-C associations with VTE may partly reflect broader metabolic and obesity-related pathways. Positive control analyses of established thrombophilia variants demonstrated expected associations. CONCLUSIONS: Across 2 large biobanks, genetically mediated differences in LDL-C were not consistently associated with VTE risk, suggesting that genetically mediated differences in LDL-C are unlikely to exert a large effect on venous thrombosis risk, although small effects cannot be excluded. Complementary common variant analyses further suggest that previously reported LDL-C associations with VTE may partly reflect broader metabolic and obesity-related pathways rather than LDL-C itself.
引用
- Sui Y, Kany S, Khurshid S, et al. Genetically Mediated Differences in LDL Cholesterol and Risk of Venous Thromboembolism. J Am Coll Cardiol. 2026. PMID: 42663354. doi:10.1016/j.jacc.2026.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。